{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+infusion+%28Arm+B%29",
    "query": {
      "intervention": "Bendamustine infusion (Arm B)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+infusion+%28Arm+B%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T00:13:53.978Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02594163",
      "title": "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma Refractory",
        "Follicular B-cell Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-10",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 22,
      "location_summary": "Duarte, California • Santa Barbara, California • Torrance, California + 18 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02594163"
    },
    {
      "nct_id": "NCT04792489",
      "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Diffuse Large B Cell Lymphoma (DLBCL)",
        "Relapsed Diffuse Large B Cell Lymphoma",
        "High Grade B-cell Lymphoma (HGBCL)",
        "Primary Mediastinal B-cell Lymphoma (PMBCL)",
        "Transformed Lymphoma",
        "Central Nervous System Lymphoma",
        "Mantle Cell Lymphoma (MCL)",
        "Richter Transformation",
        "Transplant-ineligible 2nd Line DLBCL"
      ],
      "interventions": [
        {
          "name": "zamtocabtagene autoleucel (MB-CART2019.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Miltenyi Biomedicine GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2021-05-25",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04792489"
    },
    {
      "nct_id": "NCT00856830",
      "title": "Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Extensive Stage Lung Cancer",
        "Chemonaive"
      ],
      "interventions": [
        {
          "name": "Novel Drug Combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-04",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Marietta, Georgia",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856830"
    },
    {
      "nct_id": "NCT01520922",
      "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Leukaemia, Lymphocytic, Chronic"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2012-03",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-19",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 6,
      "location_summary": "Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520922"
    },
    {
      "nct_id": "NCT05139017",
      "title": "A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zilovertamab vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor (G-CSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2022-01-14",
      "completion_date": "2027-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 26,
      "location_summary": "Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05139017"
    },
    {
      "nct_id": "NCT02733042",
      "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia, Lymphocytic, Chronic, B-Cell"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2016-05-11",
      "completion_date": "2022-08-21",
      "has_results": true,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 19,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02733042"
    },
    {
      "nct_id": "NCT06854003",
      "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Sonrotoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christine Ryan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-04-22",
      "completion_date": "2039-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06854003"
    },
    {
      "nct_id": "NCT07725406",
      "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",
        "Relapsed or Refractory Multiple Myeloma (MM)"
      ],
      "interventions": [
        {
          "name": "Lymphodepleting chemotherapy: Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Lymphodepleting chemotherapy: Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Lymphodepleting chemotherapy: Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Lisocabtagene Maraleucel",
          "type": "OTHER"
        },
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "OTHER"
        },
        {
          "name": "Ciltacabtagene Autoleucel",
          "type": "OTHER"
        },
        {
          "name": "Low-Dose Total Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-08-01",
      "completion_date": "2033-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07725406"
    },
    {
      "nct_id": "NCT02626455",
      "title": "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Copanlisib (BAY80-6946)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 551,
      "start_date": "2016-01-06",
      "completion_date": "2023-11-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 10,
      "location_summary": "Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "West Covina",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Thomasville",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02626455"
    },
    {
      "nct_id": "NCT06191744",
      "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Follicular Lymphoma (FL)"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1095,
      "start_date": "2024-02-05",
      "completion_date": "2037-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-26T00:13:53.978Z",
      "location_count": 58,
      "location_summary": "Fresno, California • San Diego, California • Santa Barbara, California + 48 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06191744"
    }
  ]
}